Literature DB >> 9240332

Regression of an abdominal aortic aneurysm after endograft exclusion.

R A White1, C E Donayre, I Walot, G E Kopchok, E P Wilson, C deVirgilio.   

Abstract

We describe the regression of a 6.5 cm diameter abdominal aortic aneurysm in a 71-year-old patient within 1 year of aortic endograft placement. The aneurysm decreased in size to 4 cm at 3 months and was 3.3 cm at 8 months on duplex examination. By 1 year a spiral computed tomographic study confirmed complete regression of the aneurysm, with mild shortening and angulation of the unsupported body of the aortoiliac endoluminal prosthesis. The case demonstrates a potential of endograft treatment of aortic aneurysms and decribes the changes in prosthesis configuration and position that occurred after implantation.

Entities:  

Mesh:

Year:  1997        PMID: 9240332     DOI: 10.1016/s0741-5214(97)70157-5

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  4 in total

Review 1.  Aortic aneurysm morphology for planning endovascular procedures.

Authors:  R A White; C E Donayre; I Walot; G E Kopchok; C deVirgilio; C M Mehringer
Journal:  Tex Heart Inst J       Date:  1997

2.  Modular bifurcation endoprosthesis for treatment of abdominal aortic aneurysms.

Authors:  R A White; C E Donayre; I Walot; G E Kopchok; E Wilson; M Heilbron; F Hussain; C deVirgilio; R Buwalda; T J Fogarty
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

3.  Role of multidetector computed tomography in evaluating complications following endovascular repair of aortic aneurysm.

Authors:  Zarina Abdul Aziz; Purushotham R Naidu; Jagadish Prasad; Arjun Kalyanpur
Journal:  J Cardiovasc Dis Res       Date:  2010-07

4.  TIMP‑3 suppresses the proliferation and migration of SMCs from the aortic neck of atherosclerotic AAA in rabbits, via decreased MMP‑2 and MMP‑9 activity, and reduced TNF‑α expression.

Authors:  Huan Zhai; Xun Qi; Zixuan Li; Wei Zhang; Chenguang Li; Lu Ji; Ke Xu; Hongshan Zhong
Journal:  Mol Med Rep       Date:  2018-06-26       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.